Bone Density Testing (DEXA Scan)

Bone density testing using dual-energy X-ray absorptiometry — commonly abbreviated as DEXA or DXA — measures the mineral content of bone tissue to quantify fracture risk and detect bone loss before it reaches a clinically dangerous threshold. The procedure is central to the diagnosis and monitoring of osteoporosis and bone health, a condition affecting an estimated 10 million adults in the United States according to the National Osteoporosis Foundation. Understanding what a DEXA scan measures, how it is performed, and how its results are interpreted is essential for patients, clinicians, and health systems navigating bone-related risk management within a framework shaped by federal coverage policy and clinical guidelines.

Definition and scope

A DEXA scan is a low-radiation imaging study that quantifies bone mineral density (BMD) at specific skeletal sites — most commonly the lumbar spine (L1–L4 vertebrae) and the proximal femur, which includes the femoral neck and total hip. The test produces a T-score and a Z-score, both of which anchor clinical interpretation.

The T-score compares an individual's BMD against the mean peak bone mass of a healthy 30-year-old reference population of the same sex. The Z-score compares BMD against age- and sex-matched norms. The World Health Organization (WHO) established the diagnostic classification thresholds for postmenopausal women (WHO Technical Report Series 843, 1994):

Normal: T-score at or above −1.0
Low bone mass (osteopenia): T-score between −1.0 and −2.5
Osteoporosis: T-score at or below −2.5
Severe osteoporosis: T-score at or below −2.5 with one or more fragility fractures

The International Society for Clinical Densitometry (ISCD) publishes official positions on how T-score thresholds apply across different populations — including men, premenopausal women, and children — where Z-scores carry greater diagnostic weight than T-scores (ISCD Official Positions 2019).

DEXA testing falls under the broader category of imaging in orthopedic evaluation, alongside tools such as X-ray for bone and joint conditions and MRI for musculoskeletal injuries. Unlike those modalities, DEXA does not evaluate morphology or soft tissue — its sole diagnostic output is quantified mineral density expressed in grams per square centimeter (g/cm²).

How it works

A DEXA scanner directs two X-ray beams of different energy levels at the target skeletal site. Because bone mineral and soft tissue attenuate these beams at different rates, the system's software calculates the differential absorption to isolate bone mineral content. The process is non-invasive, requires no injection or contrast agent, and delivers a radiation dose of approximately 1–10 microsieverts (μSv) per scan — a fraction of the 10 μSv average daily background radiation exposure from natural sources cited by the Health Physics Society.

The standard protocol for a spine and hip DEXA scan proceeds in the following phases:

Patient positioning: The patient lies supine on a padded table. A positioning block elevates the legs to flatten the lumbar spine for L1–L4 imaging; the hip is internally rotated approximately 15–25 degrees for femoral neck measurement.
Scan acquisition: The scanner arm passes over the target region, typically taking 10–20 minutes for a bilateral hip and spine study.
Image review: A trained technologist verifies scan quality, checks for positioning artifacts, and flags degenerative changes (osteophytes, aortic calcifications) that can falsely elevate apparent BMD.
Report generation: The system calculates T-scores and Z-scores against manufacturer-embedded reference databases and generates a printable report for interpreting clinician review.

Scan quality standards and technologist competency are governed by ISCD certification programs. Facilities performing Medicare-reimbursed bone density studies must meet equipment and personnel standards outlined under CMS coverage policy for bone mass measurement (42 CFR §410.31).

Common scenarios

DEXA testing is ordered across a defined set of clinical presentations rather than as a universal screening tool. The U.S. Preventive Services Task Force (USPSTF) recommends screening for osteoporosis in women aged 65 and older, and in younger postmenopausal women whose 10-year fracture risk equals or exceeds that of a 65-year-old white woman with no additional risk factors (Grade B recommendation, 2018).

Beyond routine screening, DEXA is indicated in the following clinical scenarios:

Fragility fracture history: Any low-trauma fracture — occurring from a fall from standing height or less — warrants BMD measurement to quantify underlying bone loss and inform treatment thresholds.
Long-term glucocorticoid use: Patients receiving 5 mg or more of prednisone (or equivalent) per day for 3 or more months are at substantially elevated fracture risk; the American College of Rheumatology (ACR) guidelines specify DEXA as part of glucocorticoid-induced osteoporosis management (ACR Guideline 2022).
Hyperparathyroidism and metabolic bone disease: Conditions that alter calcium and phosphate metabolism — including primary hyperparathyroidism, malabsorption syndromes, and chronic kidney disease — may require serial DEXA monitoring.
Monitoring treatment response: Patients on bisphosphonate, denosumab, or anabolic therapy for osteoporosis typically undergo repeat DEXA at 1–2 year intervals to assess BMD change over time.
Preventing falls and fractures in older adults: DEXA results inform multifactorial fall-prevention strategies when integrated with functional assessments and home environment evaluation.

The Fracture Risk Assessment Tool (FRAX), developed by the University of Sheffield and adopted by the WHO, uses BMD alongside clinical risk factors to generate a 10-year probability of major osteoporotic fracture and hip fracture — enabling more nuanced treatment decisions than BMD alone (FRAX Tool).

Decision boundaries

Interpreting DEXA results requires understanding what the scan can and cannot establish. Several technical and clinical boundaries define the limits of the test.

Scan vs. fracture risk: A T-score classifies bone density relative to a reference population but does not directly measure structural bone quality. Two individuals with identical T-scores of −2.5 may carry substantially different fracture risks depending on bone geometry, trabecular microarchitecture, fall tendency, and comorbidities. FRAX adjusts for this gap but does not eliminate it.

Peripheral DEXA vs. central DEXA: Portable peripheral devices (pDXA) measure BMD at the wrist, heel, or finger. These are used for population screening but are not interchangeable with central DEXA of the spine and hip for diagnostic classification or treatment monitoring. ISCD does not recognize pDXA T-scores as equivalent to central DXA T-scores for WHO diagnostic criteria.

Artifacts and false elevation: Degenerative disc disease, vertebral compression fractures, aortic calcification, and prior spinal hardware implants can all falsely elevate lumbar spine BMD readings. In patients with significant lumbar arthritis, the lateral spine projection or hip-only measurement may provide more accurate results.

Repeat scan intervals: Medicare and most commercial payers reimburse central DEXA no more frequently than every 24 months under standard policy, consistent with the minimum interval needed to detect clinically meaningful BMD change with current scanner precision (CMS Bone Mass Measurement Coverage).

Men and premenopausal women: The WHO T-score thresholds were derived from postmenopausal female data. The ISCD recommends using Z-scores rather than T-scores as the primary reporting metric for men under 50 and premenopausal women, with a Z-score below −2.0 defined as "below the expected range for age." Understanding this distinction is critical for accurate interpretation in non-standard populations.

The regulatory context for orthopedics — including CMS coverage determinations and ACR appropriateness criteria — directly governs which patients qualify for covered bone density testing and at what intervals, making familiarity with these frameworks a functional requirement for ordering clinicians. A broader overview of orthopedic diagnostic and treatment tools is available at the orthopedics resource index.

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)